Loading
Radiation oncologist who showed MRI-guided prostate radiotherapy causes fewer side effects.
Amar Kishan is Professor and Vice Chair of Clinical and Translational Research in Radiation Oncology at UCLA, part of the UCLA Jonsson Comprehensive Cancer Center. A radiation oncologist specialising in prostate radiotherapy, MR-guided radiotherapy and hypofractionation, he led MIRAGE, the randomised trial of MRI-guided versus CT-guided stereotactic body radiotherapy for prostate cancer, which showed fewer side effects with MRI guidance. His papers report the MIRAGE trial in JAMA Oncology and an individual patient data meta-analysis of androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer in Lancet Oncology. His record also links to the ArteraAI Prostate test.
Shares UCLA Jonsson Comprehensive Cancer Center, MR-guided adaptive radiotherapy, SBRT / SABR (stereotactic radiotherapy), Prostate cancer.
Shares ArteraAI Prostate, Prostate cancer.
Shares ArteraAI Prostate, Prostate cancer.
Shares UCLA Jonsson Comprehensive Cancer Center, Prostate cancer.
Shares UCLA Jonsson Comprehensive Cancer Center, Prostate cancer.
Shares UCLA Jonsson Comprehensive Cancer Center, JAMA Oncology, Prostate cancer.
Shares ArteraAI Prostate, Prostate cancer.